- Home
- TOMZ vs MBRX Comparison
TOMZ vs MBRX Comparison
Compare TOMZ & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | MBRX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 13.1M |
| IPO Year | 2009 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | MBRX |
|---|---|---|
| Price | $0.80 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 349.3K | 259.4K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.25 |
| 52 Week High | $1.20 | $7.98 |
Technical Indicators
Market Signals| Indicator | TOMZ | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 59.27 |
| Support Level | $0.69 | $2.24 |
| Resistance Level | $0.82 | $2.95 |
| Average True Range (ATR) | 0.10 | 0.22 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 21.84 | 57.93 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.